Cargando…

TP53 Mutation in Acute Myeloid Leukemia: An Old Foe Revisited

SIMPLE SUMMARY: The TP53 gene encodes the p53 protein, which plays a diverse role in responding to various cellular stresses. p53 consists of several functional domains, including a tetramerization domain for forming heterotetramers and a DNA-binding domain for bindings to p53-responsive elements. T...

Descripción completa

Detalles Bibliográficos
Autor principal:	Shin, Dong-Yeop
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10571655/ https://www.ncbi.nlm.nih.gov/pubmed/37835510 http://dx.doi.org/10.3390/cancers15194816

Ejemplares similares

TP53-Mutated Myelodysplasia and Acute Myeloid Leukemia
por: Testa, Ugo, et al.
Publicado: (2023)

TP53 in Acute Myeloid Leukemia: Molecular Aspects and Patterns of Mutation
por: George, Binsah, et al.
Publicado: (2021)

Personalized Medicine for TP53 Mutated Myelodysplastic Syndromes and Acute Myeloid Leukemia
por: Cluzeau, Thomas, et al.
Publicado: (2021)

Targeting TP53-Mutated Acute Myeloid Leukemia: Research and Clinical Developments
por: Granowicz, Eric M, et al.
Publicado: (2022)

Are We Moving the Needle for Patients with TP53-Mutated Acute Myeloid Leukemia?
por: Shallis, Rory M., et al.
Publicado: (2022)

Functional Classification of TP53 Mutations in Acute Myeloid Leukemia
por: Dutta, Sayantanee, et al.
Publicado: (2020)

How I Treat TP53-Mutated Acute Myeloid Leukemia and Myelodysplastic Syndromes
por: Loschi, Michael, et al.
Publicado: (2022)

TP53 Alterations in Myelodysplastic Syndromes and Acute Myeloid Leukemia
por: Rahmé, Ramy, et al.
Publicado: (2023)

Preexisting TP53 mutation in therapy-related acute myeloid leukemia
por: Schulz, Eduard, et al.
Publicado: (2014)

Clinical implications of subclonal TP53 mutations in acute myeloid leukemia
por: Prochazka, Katharina T., et al.
Publicado: (2019)

TP-0903 Is Active in Preclinical Models of Acute Myeloid Leukemia with TP53 Mutation/Deletion
por: Eisenmann, Eric D., et al.
Publicado: (2022)

Rare Presentation of Acute Myeloid Leukemia With TP53 Mutation and Dermatologic Manifestations
por: Lott, Ronald, et al.
Publicado: (2023)

Impact of TP53 mutations in acute myeloid leukemia patients treated with azacitidine
por: Bories, Pierre, et al.
Publicado: (2020)

TP53 Mutations in Acute Myeloid Leukemia: Still a Daunting Challenge?
por: Molica, Matteo, et al.
Publicado: (2021)

TP53 mutation in newly diagnosed acute myeloid leukemia and myelodysplastic syndrome
por: Niparuck, Pimjai, et al.
Publicado: (2021)

The Prognostic Value of TP53 Mutations in Adult Acute Myeloid Leukemia: A Meta-Analysis
por: Qin, Guoxiang, et al.
Publicado: (2022)

TP53-Mutated Myelodysplastic Syndrome and Acute Myeloid Leukemia: Biology, Current Therapy, and Future Directions
por: Daver, Naval G., et al.
Publicado: (2022)

Comparison of acute myeloid leukemia and myelodysplastic syndromes with TP53 aberrations
por: Dutta, Sayantanee, et al.
Publicado: (2022)

Intestinal helminths – An old foe revisited
por: Parija, Subhash Chandra
Publicado: (2017)

Association Analyses of TP53 Mutation With Prognosis, Tumor Mutational Burden, and Immunological Features in Acute Myeloid Leukemia
por: Wen, Xiang-mei, et al.
Publicado: (2021)

Therapeutic Targeting of TP53-mutated Acute Myeloid Leukemia by Inhibiting HIF-1α with Echinomycin
por: Wang, Yin, et al.
Publicado: (2020)

Identification of key pathways and genes in TP53 mutation acute myeloid leukemia: evidence from bioinformatics analysis
por: Huang, Rui, et al.
Publicado: (2017)

Low frequency TP53 hotspot mutation contributes to chemoresistance through clonal expansion in acute myeloid leukemia
por: Yan, Bowen, et al.
Publicado: (2020)

Decitabine salvage for TP53-mutated, relapsed/refractory acute myeloid leukemia after cytotoxic induction therapy
por: Ferraro, Francesca, et al.
Publicado: (2022)

Human acute myeloid leukemia stem cells: evolution of concept
por: Shin, Dong-Yeop
Publicado: (2022)

Genomic landscape of TP53-mutated myeloid malignancies
por: Abel, Haley J., et al.
Publicado: (2023)

Genomic landscape of TP53-mutated myeloid malignancies
por: Abel, Haley J., et al.
Publicado: (2023)

Somatic TP53 mutations are preleukemic events in acute lymphoblastic leukemia
por: Chitadze, Guranda, et al.
Publicado: (2023)

TP53-mutant myelodysplastic syndrome and acute myeloid leukemia: the black hole of hematology
por: Patel, Shyam A., et al.
Publicado: (2022)

TP53 mutation characteristics in therapy-related myelodysplastic syndromes and acute myeloid leukemia is similar to de novo diseases
por: Ok, Chi Young, et al.
Publicado: (2015)

Role of ASXL1 and TP53 mutations in the molecular classification and prognosis of acute myeloid leukemias with myelodysplasia-related changes
por: Devillier, Raynier, et al.
Publicado: (2015)

Monosomal karyotype and chromosome 17p loss or TP53 mutations in decitabine-treated patients with acute myeloid leukemia
por: Becker, Heiko, et al.
Publicado: (2020)

TP53 copy number and protein expression inform mutation status across risk categories in acute myeloid leukemia
por: Tashakori, Mehrnoosh, et al.
Publicado: (2022)

Kevetrin induces apoptosis in TP53 wild-type and mutant acute myeloid leukemia cells
por: Napolitano, Roberta, et al.
Publicado: (2020)

TP53 mutations in de novo acute myeloid leukemia patients: longitudinal follow-ups show the mutation is stable during disease evolution
por: Hou, H-A, et al.
Publicado: (2015)

Ascorbate Inhibits Proliferation and Promotes Myeloid Differentiation in TP53-Mutant Leukemia
por: Smith-Díaz, Carlos C., et al.
Publicado: (2021)

MDM4 Overexpressed in Acute Myeloid Leukemia Patients with Complex Karyotype and Wild-Type TP53
por: Li, Li, et al.
Publicado: (2014)

Additional cytogenetic features determine outcome in patients allografted for TP53 mutant acute myeloid leukemia
por: Loke, Justin, et al.
Publicado: (2022)

Treatment outcomes for newly diagnosed, treatment-naïve TP53-mutated acute myeloid leukemia: a systematic review and meta-analysis
por: Daver, Naval G., et al.
Publicado: (2023)

Synergistic effects of PRIMA-1(Met) (APR-246) and 5-azacitidine in TP53-mutated myelodysplastic syndromes and acute myeloid leukemia
por: Maslah, Nabih, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_qqv9ncvtc22peg316nvm94u6pf